Home>Topics>Funds>iShares Nasdaq Biotechnology

iShares Nasdaq Biotechnology

  1. All
  2. Commentary
  3. Fund Reports
  4. ETF Reports
  5. Headlines
  1. Therapeutic cloning breakthrough

    Headlines

    Thu, 17 Apr 2014

    match over 50% of the U.S. population according to the co-author of the study, Dr. Robert Lanza. Healthcare ETFs: IYH , IBB , XLV , XBI , VHT , BIB , PJP , BBH , FBT , PBE , XPH , CURE , FXH , IHE , RXL , IRY , IXJ , PPH , IHI , BIS , IHF , FHLC , XHS

  2. Expect Biotech Rally To Lead To Further Selling Of Research Stage Companies

    Headlines

    Thu, 17 Apr 2014

    By Mitch DeVan : iShares Nasdaq Biotechnology ( IBB ) looks ready to reverse the downtrend ..... then shares have slide over 20%. IBB is currently sitting right above ..... traded back to its highs of 2013. IBB had a three and a half month rally

  3. New clinical trial format may boost cancer drug development

    Headlines

    Thu, 17 Apr 2014

    be quickly dropped while those showing efficacy will be fast-tracked into larger-scale testing. Healthcare ETFs: IYH , IBB , XLV , XBI , BIB , VHT , PJP , BBH , FBT , PBE , XPH , CURE , FXH , IHE , RXL , PPH , BIS , FHLC , PSCH , RYH , PTH , DRGS

  4. IBB iShares Nasdaq Biotechnology ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    Still, we think that IBB 's price tag is quite reasonable ..... New York Stock Exchange. IBB 's index is one of eight ..... industry can consider adding iShares Nasdaq Biotechnology to their portfolios as a tactical ..... more sway. As a result, IBB has been less volatile over

  5. XBI SPDR S&P Biotech ETF ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    market-cap-weighted option is iShares Nasdaq Biotechnology IBB , which holds 121 Nasdaq-listed ..... market cap of $14.4 billion. IBB charges an expense ratio of 0 ..... holding cost of just 0.27%. IBB has a low price tag, historically

  6. FBT First Trust NYSE Arca Biotech Index ETF Analysis, Report, Research, 5 Star Rating – Morningstar

    ETF Reports

    Wed, 16 Apr 2014

    market-cap-weighted option is iShares Nasdaq Biotechnology IBB , which holds 121 Nasdaq-listed ..... market cap of $14.4 billion. IBB charges an expense ratio of 0 ..... holding cost of just 0.27%. IBB has a low price tag, historically

  7. Keryx Biopharmaceuticals: Is The High Valuation Justified?

    Headlines

    Wed, 16 Apr 2014

    By Kanak Kanti De : The current selloff in the biotech, as evidenced by the 13.72% fall in iShares NASDAQ Biotechnology Index ETF ( IBB ) in one month, has unveiled many buying opportunities. However, at the same time it has also

  8. Gilead: This Baby Has Been Thrown Away With The Bathwater

    Headlines

    Wed, 16 Apr 2014

    pressure lately and it seems to make the "headlines" daily as the cause for so much of the NASDAQ weakness. Yes the index ( IBB ) has skyrocketed after a breakout in Nov 2013 tacking on a 30% gain in a mere 3 month time frame . These types of parabolic

  9. Is Now The Time To Buy Ironwood Pharmaceuticals?

    Headlines

    Tue, 15 Apr 2014

    By Kevin Quon : Pharmaceutical companies with recently commercialized products can often be promising investment opportunities. One such company that has recently launched a new treatment option is Ironwood Pharmaceuticals ( IRWD ) . Ironwood Pharmaceuticals is a developing company looking to lead

  10. The Sell-Off In Biotech Is Coming To An End

    Headlines

    Mon, 14 Apr 2014

    By Derek Tomczyk: The biotech ETF IBB has taken a beating over the past couple of months with a total decline of 20% since Feb 25th taking the Nasdaq ( QQQ ) down with

« Prev12345Next »
Content Partners